



X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences

September 17, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 17, 2019-- [X4 Pharmaceuticals, Inc.](#) (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the management team is scheduled to conduct one-on-one meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, and to present and conduct one-on-one meetings at the 2019 Cantor Global Healthcare Conference.

Details related to the team's participation are as follows:

Conference: Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

Location: New York, NY

Date: September 23rd

Conference: 2019 Cantor Global Healthcare Conference

Location: New York, NY

Presentation Date & Time: October 2nd at 4:10 pm EDT

About X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company's oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4's most advanced product candidate, mavoxixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavoxixafor in Severe Congenital Neutropenia (SCN) and Waldenström's macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria. For more information, please visit www.x4pharma.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190917005244/en/>

Source: X4 Pharmaceuticals, Inc.

Investors:

Stephanie Carrington
Westwicke, an ICR company
646-277-1282
Stephanie.Carrington@icrinc.com

Media:

Darcie Robinson
Westwicke, an ICR company
203-919-7905
Darcie.robinson@icrinc.com